Zacks Investment Research downgraded shares of CARDIOVASCLR SY (CSII) from OUTPERFORM to NEUTRAL on February 05, 2014, with a target price of $36.80.
Cardiovascular Systems, Inc., formerly known as Replidyne Inc., is headquartered in Saint Paul, Minnesota. It is a medical device company focusing on developing and commercializing interventional treatment systems for vascular disease. Its initial product, the Diamondback 360 Orbital Atherectomy System, is a minimally invasive catheter system for the treatment of peripheral arterial disease and a range of plaque types, including calcified vessel lesions. The Diamondback 360 removes soft and calcified plaque in plaque-lined vessels through the orbital rotation of a diamond grit coated offset crown. The company refined its "orbital" technology to address the growing market need of providing a safer more effective atherectomy device.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on CARDIOVASCLR SY (CSII),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment